Brief: Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union

Acadia Pharmaceuticals

02/02/2026 21:16

Feb 2 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:

ACADIA PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME IN THE EUROPEAN UNION

ACADIA PHARMACEUTICALS INC - RECEIVES NEGATIVE TREND VOTE ON TROFINETIDE MAA

ACADIA PHARMACEUTICALS INC - TO REQUEST RE-EXAMINATION OF CHMP OPINION

Source text: ID:nBw4c9N3xa

Further company coverage: ACAD.O

 ((Reuters.Briefs@thomsonreuters.com;))